The effect of surface area expansion with pericardial membrane (preclude) in Ahmed glaucoma valve implant surgery.
OBJECTIVE
To compare the efficacy of Ahmed glaucoma valve (AGV) implant with and without surface area expansion using pericardial membrane (Preclude) in the treatment of complicated glaucoma.


METHODS
Ten eyes of AGV implant surgery using pericardial membrane (Preclude) that were designed to have surface area of 300 mm (e-AGV group) and 10 eyes of AGV implant surgery without surface area extension (AGV group) were enrolled in this prospective, randomized controlled trial study.


RESULTS
Two (20%) of 10 eyes in the e-AGV group, and 8 (80%) of 10 eyes in the AGV group experienced the hypertensive phase (P = 0.007). Complete success rate was 90% in the e-AGV group and 70% in the AGV group (P = 0.291). Mean number of preoperative antiglaucoma medication was 2.4 +/- 0.5 and 1.9 +/- 0.3 for the e-AGV and AGV groups, respectively, and that of postoperative antiglaucoma medication was 0.1 +/- 0.3 and 0.4 +/- 0.7 for the e-AGV and AGV groups, respectively, at final follow-up (P = 0.229).


CONCLUSIONS
Surface area expansion with pericardial membrane (Preclude) in AGV implant surgery resulted in a statistically significantly lower rate of hypertension without causing any postoperative complications.
Hwang
Jeong-Min
JM
Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul, Korea.
Kee
Changwon
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D005901:Glaucoma / Q000601:surgery*; D020327:Glaucoma Drainage Implants; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures; D010496:Pericardium; D011446:Prospective Studies; D019919:Prosthesis Implantation / Q000379:methods*; D015626:Tissue Expansion / Q000379:methods*; D016896:Treatment Outcome